- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05889000
Quality of Life Questionnaire and Disease Severity Scale
Quality of Life Questionnaire and Disease Severity Scale for Patients With Chronic Pelvic Venous Disorders: Design and Validation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This retrospective study will include patients with pelvic varicose veins seen between 2018 and 2020.
2 groups of patients will be formed. The main group will be women with verified CPVD, the comparison group - 93 participants without signs of CPVD.
All patients will respond to the previously developed Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS) as submitted questionnaires.
Validation of the PVVQ questionnaire and the PVCSS scale will be carried out in accordance with the methodology for studying the quality of life and clinical scales in accordance with international standards. The main psychometric properties of both instruments in terms of validity, reliability and sensitivity will be assessed.
The validation protocol will include certain steps: 1) pre-testing, 2) assessing the reliability of the questionnaire, 3) assessing the validity, 4) assessing the sensitivity.
- Preliminary testing. For preliminary testing, patients will fill out questionnaires, followed by finding out how clear the questions asked are, how accurate and ethical the formulations are, in their opinion. The convenience of working with the questionnaire from the point of view of the research doctor will also be assessed.
Reliability assessment. The reliability assessment will be carried out according to three criteria - internal consistency, discriminant validity and internal consistency.
To assess the degree of internal consistency, the Cronbach's alpha coefficient will be used, which is calculated by the formula: α = N * r / (1 + r * (N - 1)), where N is the number of components under study, r is the average correlation coefficient between the components. The study will assess the reliability of the questionnaire and the scale as a whole, as well as the impact on the overall reliability of each individual domain. Domain correlation will be assessed using Spearman's rank correlation method (r).
To assess discriminant validity, the level of quality of life and disease severity of patients with VBT will be compared with similar levels of healthy participants.
Assessment of internal consistency will be performed by retesting stable patients without treatment after 14 days, followed by calculation of Cronbach's alpha.
Assessment of validity. To assess the validity, the reliability of the construct will be studied by determining the criterion validity, i.e. identifying the correlation coefficient or relationships between the scales of both questionnaires with some external criterion. The scales of the SF-36 questionnaire will be used as external criteria for assessing the quality of life, and elements of visual analogue scales will be used to assess the severity of the disease.
To study the degree of representation of the studied psychological construct in the test results, both types of construct validity will be determined: convergent and discriminant.
- Sensitivity assessment. To assess the sensitivity, a comparison of the indicators of the questionnaire questionnaires at the points before treatment and 2 months after the treatment will be carried out.
Based on this examination of the data, objective information on the validity, reliability and sensitivity of PVVQ and PVCSS will be obtained.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Republic Of Tatarstan
-
Kazan, Republic Of Tatarstan, Russian Federation
- State Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- presence of PVV;
- completed Patient Informed Consent Form;
- age from 18 to 70 years;
- ability to understand and answer the questions of the proposed questionnaire.
Exclusion Criteria:
- absence of confirmed PVV;
- lack of Patient Informed Consent Form;
- under the age of 18 or over 70 years old;
- pregnancy at any stage and 12-month postpartum period;
- presence of a gynecological or other concomitant (urological, neurological, procto-logical, etc.) significant pathology that has similar clinical symptoms with CPVD and re-quires specific treatment;
- presence of severe concomitant gastrointestinal or hematopoietic system pathology, terminal stages of cardiovascular, respiratory, renal and hepatic failure, stage IV malignant tumor, obliterating diseases of lower limbs arteries;
- dementia and other mental disorders that limit the ability to understand the essence of the research, fill out Patient Informed Consent Form and answer the questionnaire
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
main group
304 patients with verified CPVD
|
questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
|
comparison group
93 participants without signs of CPVD.
|
questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
internal consistency assessment
Time Frame: At baseline
|
To assess the degree of internal consistency, the Cronbach's alpha coefficient will be used, which is calculated by the formula: α = N * r / (1 + r * (N - 1)), where N is the number of components under study, r is the average correlation coefficient between the components.
The study will assess the reliability of the questionnaire and the scale as a whole, as well as the impact on the overall reliability of each individual domain.
Domain correlation will be assessed using Spearman's rank correlation method (r).
|
At baseline
|
discriminant validity evaluation internal consistency score
Time Frame: At baseline
|
To assess discriminant validity, the level of quality of life and disease severity of patients with CPVD will be compared with similar levels of healthy participants.
|
At baseline
|
internal consistency score
Time Frame: At baseline and after 14 days
|
Assessment of internal consistency will be performed by retesting stable patients without treatment after 14 days, followed by calculation of Cronbach's alpha.
|
At baseline and after 14 days
|
determination of criterion validity
Time Frame: At baseline
|
To assess the validity, the reliability of the construct will be studied by determining the criterion validity, i.e. identifying the correlation coefficient or relationships between the scales of both questionnaires with some external criterion.
The scales of the SF-36 questionnaire will be used as external criteria for assessing the quality of life, and elements of visual analogue scales will be used to assess the severity of the disease.
|
At baseline
|
Sensitivity assessment.
Time Frame: At baseline and after 2 months
|
To assess the sensitivity, a comparison of the indicators of the questionnaire questionnaires at the points before treatment and 2 months after the treatment will be carried out.
|
At baseline and after 2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Aigul A Mutygullina, PhD, Kazan State Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 10012022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Congestion Syndrome
-
Interregional Clinical Diagnostic Center, RussiaCompletedPelvic Congestion SyndromeRussian Federation
-
Group of Research in Minimally Invasive TechniquesCompletedPelvic Congestion SyndromeSpain
-
Assiut UniversityCompletedPelvic CongestionEgypt
-
Pirogov Russian National Research Medical UniversityCompletedPelvic Pain | Pelvic Congestion Syndrome | Varicose Veins PelvicRussian Federation
-
Group of Research in Minimally Invasive TechniquesUnknownObservational Study | Pelvic Congestion Syndrome | Embolization, Therapeutic | Pelvic Varicose Veins | Follow-up StudySpain
-
ArtVentive Medical Group, Inc.UnknownVaricocele | Pelvic Congestion SyndromeBelgium, Poland, Switzerland
-
The Whiteley ClinicUnknownVaricose Veins | Venous Reflux | Pelvic Congestion SyndromeUnited Kingdom
-
GlaxoSmithKlineCompletedCongestion, NasalUnited States
-
Catharina Ziekenhuis EindhovenCompletedPulmonary CongestionNetherlands
-
Omega PharmaCompleted
Clinical Trials on questionnaire responses
-
University Hospital, AngersCompleted
-
FondationbHopaleNot yet recruitingStroke Rehabilitation | Postural EquilibriumFrance
-
New York Obesity and Nutrition Research CenterColumbia University; St. Luke's-Roosevelt Hospital CenterUnknown
-
Pennington Biomedical Research CenterWeight Watchers InternationalEnrolling by invitation
-
Chestnut Health SystemsNational Institute of Mental Health (NIMH)Not yet recruitingChild Abuse | Mental Health | Implementation Science | Decision Making | Family | Child Welfare | Decision Making, Shared | Social Facilitation | Policy | Decision Support Technique | Organizations | Consensus
-
Istituto Auxologico ItalianoRecruiting
-
Hospices Civils de LyonWithdrawnLeukemia, Myeloid
-
SK Bioscience Co., Ltd.International Vaccine InstituteWithdrawn